Indomethacin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Indomethacin: Brachydactyly-syndactyly syndrome
One-Sentence Summary
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) used for inflammatory joint and soft-tissue conditions such as rheumatoid arthritis, ankylosing spondylitis, gout, osteoarthritis and bursitis. It is also used to close patent ductus arteriosus. The TxGNN model predicts it may be effective for brachydactyly-syndactyly syndrome, a rare congenital limb malformation. However, there are 0 clinical trials and 0 publications supporting this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Brachydactyly-syndactyly syndrome |
| TxGNN Prediction Score | 0.9997 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Indomethacin belongs to the NSAID class and is generally understood to reduce prostaglandin-driven inflammation by inhibiting cyclooxygenase (COX) enzymes. This is why it works in inflammatory arthritis and gout.
Brachydactyly-syndactyly syndrome, however, is a rare congenital limb malformation with a genetic developmental basis. It is not an inflammatory disease, and no mechanistic link between COX inhibition and limb patterning has been established. The very high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
The rationale for this prediction is therefore weak. It should be treated as a computational signal only, with no biological or clinical support at present.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Indomethacin is marketed in India with 20 valid single-ingredient registrations and no cancelled ones. The approved indication text is not specified for any of them. Five representative authorizations:
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| Registration No. 109975 | Indometh 75mg Tablet SR | Sustained-release tablet |
| Registration No. 108477 | Inmeth Suppositories | Suppository |
| Registration No. 108966 | Inmecin 75mg Capsule | Capsule |
| Registration No. 107709 | Indocap SR Capsule | Sustained-release capsule |
| Registration No. 110796 | Indoriv 25mg Capsule | Capsule |
Available forms are mainly oral (tablets, capsules, sustained- and extended-release) plus rectal suppositories.
Safety Considerations
- Drug Interactions: 252 interactions were recorded, mostly minor or moderate. Notable moderate-level interactions include:
- Corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide)
- Acetylsalicylic acid
- Metformin and sulfonylureas (chlorpropamide, glimepiride)
- Mesalazine and balsalazide
- Aprepitant
- Potassium salts (potassium citrate, potassium bicarbonate)
Minor interactions include H2 blockers (famotidine, ranitidine, cimetidine).
- Conditions flagged as contraindication-related in the knowledge graph (not label text): this is a general NSAID-type signal and should be verified against the package insert.
- Cardiovascular: hypertension, myocardial infarction, heart disease
- Gastrointestinal: peptic and gastric ulcers, ulcerative colitis, inflammatory bowel disease
- Renal and hepatic: kidney disease, liver disease
- Bleeding and blood: coagulation disorders, thrombocytopenia, intracerebral hemorrhage
- Respiratory: asthma
- Neurological: epilepsy
Please refer to the package insert for authoritative warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical trials and no literature, and no plausible mechanistic link between COX inhibition and a genetic limb malformation. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. Indomethacin carries meaningful cardiovascular, gastrointestinal and renal risks that are not justified by any evidence of benefit here.
To proceed, the following is needed:
- Detailed mechanism of action data, and any biological evidence linking prostaglandin pathways to this syndrome
- Package insert warnings and contraindications for the marketed Indian products
- Any preclinical or case-level evidence in this condition
Note on other predictions: Among the other top-ranked predictions, juvenile idiopathic arthritis (rank 8) has the most support (L3, older reviews and one 1978 double-blind comparison). However, this is an established symptomatic NSAID use rather than a novel repurposing, and it does not show disease modification.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.